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ORIGINAL ARTICLE
Glutaraldehyde-Modified Recombinant Fel d 1:
A Hypoallergen With Negligible Biological
Activity But Retained Immunogenicity
Serge A. Versteeg, BSc,1 Ingrid Bulder, BSc,2 Martin Himly, PhD,3 Toni M. van Capel, BSc,4
R. van den Hout, PhD,5 Stef J. Koppelman, PhD,5 Esther C. de Jong, PhD,4
Fatima Ferreira, PhD,3 and Ronald van Ree, PhD1,6
Background: Recombinant allergens are under investigation for
replacing allergen extracts in immunotherapy. Site-directed muta-
genesis has been suggested as a strategy to develop hypoallergenic
molecules that will reduce the risk of side effects. For decades,
chemically modified allergen extracts have been used for the same
reason.
Aim: To evaluate whether glutaraldehyde modification is a good
strategy to produce hypoallergenic recombinant allergens with
retained immunogenicity.
Methods: Fel d 1 was cloned as a single construct linking both
chains of the molecule and expressed in Escherichia coli and Pichia
pastoris. After physicochemical purification, recombinant Fel d 1
(rFel d 1) was chemically modified using glutaraldehyde. The effect
of modification on immune reactivity was evaluated using radioal-
lergosorbent test, CAP-inhibition, competitive radioimmunoassay,
enzyme-linked immunosorbent assay, basophil histamine release,
and T-cell proliferation assays. Both natural Fel d 1 and recombinant
unmodified Fel d 1 were used as controls.
Results: rFel d 1 demonstrated similar IgE binding and biological
activity as its natural counterpart. Upon modification, IgE-binding
potency decreased to.1000-fold, which was translated into a.106-
fold reduction in the biological activity assessed by basophil hista-
mine release. In contrast, the modified recombinant did not show
a decreased but even a moderately increased capacity (1.5-fold) to
stimulate proliferation of T cells (P , 0.01). Finally, it induced
specific IgG antibodies in rabbits that recognized the unmodified
allergen.
Conclusions: Chemical modification is a practical and highly
effective approach for achieving hypoallergenicity of recombinant
allergens with retained immunogenicity.
Key Words: allergoid, Felis domesticus, hypoallergen, immunother-
apy, rFel d 1
(WAO Journal 2011; 4:113–119)
It is well established that Fel d 1 is responsible for most IgEreactivity in cat-allergic patients.1–6 Treatment of cat allergy
by immunotherapy with epithelial extracts was demonstrated
to be effective.7,8 From a regulatory perspective, treatment
with mammalian extracts is not ideal because of the potential
risk to transmit pathogens. The dominant role of Fel d 1 in
cat allergy makes the development of a recombinant Fel
d 1-based product an obvious choice. Fel d 1, a 38-kDa
glycoprotein with N-linked olisaccharides,9 was first cloned
and expressed by Morgenstern et al.10 The allergen consists
of two 19-kDa noncovalently linked heterodimers, each com-
posed of a light a-chain and a heavy b-chain,10 encoded by
2 separate genes.11 Three disulfide bridges connect the
a-chain and b-chain in an antiparallel orientation.9,12 Ex-
pressed as individual chains in Escherichia coli, IgE binding
was poor in natural Fel d 1 (nFel d 1),13,14 but combining
both chains, followed by a lengthy refolding protocol, a
recombinant was obtained with similar IgE reactivity as the
nFel d 1.1,14,15 More recently, Fel d 1 was also expressed as
a single construct. In baculovirus, both chains were connected
in an antiparallel fashion by a linker sequence,16,17 whereas in
E. coli, both chains were connected in a parallel orientation
without linker sequence.18
One of the disadvantages of specific immunotherapy is
the risk of anaphylactic reactions. By site-directed mutagen-
esis, it is now possible to produce recombinant molecules
with reduced IgE binding, so-called hypoallergens. This
approach has been reported for several inhalant and food
allergens. Mutating 6 amino acids of Bet v 1 gave a hypoal-
lergenic but structurally unchanged molecule,19,20 and similar
results were reported for the peanut allergens Ara h 1, Ara h
2, and Ara h 3.21,22 To our knowledge, this strategy has not
yet been applied to Fel d 1. The disadvantage of this approach
is that it requires considerable insight into the surface
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structure of an allergen to be able to predict which amino
acids should be mutated. Random mutagenesis might be an
alternative but requires laborious screening protocols. More-
over, reduction of IgE binding is sometimes limited and vari-
able for individual patients.19,22
Before the era of molecular biology, chemical modifi-
cation by, for example, glutaraldehyde or formaldehyde was
used as a way to reduce the IgE-binding potency of allergen
extracts.23 This was first described by March et al.24,25 Here,
we set out to evaluate the feasibility of chemical modification
with glutaraldehyde of a recombinant allergen as an alterna-
tive to the production of a hypoallergenic mutant obtained by
site-directed mutagenesis. To this end, we expressed Fel d 1
as a single construct in a parallel orientation in E. coli and
Pichia pastoris.
MATERIALS AND METHODS
Cloning and Expression of Fel d 1
In one construct, both chains (a-chain and b-chain)
were cloned together using a linker oligo26 in the pPICZaA
vector (Invitrogen, San Diego, CA). After transformation into
P. pastoris GS115 (His41) and expression in a Bioflo 3000
benchtop fermentor, cells were harvested and the supernatant
stored at 48C in 0.1% azide.
A second construct was created by directly linking the
C-terminal residue of the b-chain with the N-terminal residue
of the a-chain in the pET-19b vector. After transformation
into E. coli BL21 (DE3) (Novagen, Inc, Madison, WI) and
expression, the cell pellet was frozen overnight at 2208C,
thawed, and resuspended to one-tenth of the original culture
volume in 25 mM Tris/2 mM EDTA at pH 7.6. After sonication
and pelleting of insoluble matter by centrifugation, the super-
natant was saved for further processing of soluble rFel d 1.
Purification of Natural and Recombinant
Fel d 1
rFel d 1 was purified in 2 steps: first, hydrophobic
interaction chromatography using a Phenyl-Sepharose column
and second, ion exchange chromatography using a MonoQ
5/50 GL column (both, GE Healthcare Biosciences AB,
Uppsala, Sweden). The rFel d 1 containing fractions were
pooled, dialyzed against phosphate-buffered saline, concen-
trated (6-fold), and purity of the sample was assessed by
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE). nFel d 1 was affinity purified using monoclonal
antibody (mAb) 4F7, as previously described.1 Protein concen-
tration was measured by the BCA method27 (Pierce, Rockford,
IL), as described by the manufacturer. For all experiments,
E. coli-derived rFel d 1 was used unless indicated otherwise.
Murine mAbs
mAb 4F7 to nFel d 1 was obtained as described by de
Groot et al.6 mAbs 6B4 and 10F10 against reduced/alkylated
nFel d 1 were obtained as described by van Milligen et al.28
mAb 6B4 had been shown to be specific for the light chain
and 10F10 for the heavy chain.
SDS-PAGE and Immunoblotting
SDS-PAGE and immunoblotting were performed as
described previously.29
Glutaraldehyde Modification of rFel d 1
Glutaraldehyde modification was done similarly for
both recombinant preparations. Purified rFel d 1 (5 mL of
1.055 mg/mL from E. coli) was dialyzed on a 1-kDa Amicon
membrane with 100 mM of sodium carbonate (pH 9.0). The
residue was collected and diluted in the same buffer to 21 mL
resulting in a protein concentration of 0.250 mg/mL (13.9
mM, representing a total amount of 292 nmol). 1.37 mL of
25% glutaraldehyde (Merck, Darmstadt, Germany) was
slowly added (final amount; 3.26 mmol). As rFel d 1 contains
12 lysine residues and glutaraldehyde has 2 aldehyde groups,
the molar ratio of aldehyde to rFel d 1 is 1860. The mixture
was gently stirred overnight at room temperature. 6.54 mmol
of glycine was added in a time span of 30 minutes to quench
remaining free aldehyde groups. The mixture was stirred for 1
hour and dialyzed on a 10-kDa Amicon membrane. Protein
was not measured in the final product because reliable results
cannot be obtained for highly aggregated structures. For fur-
ther analysis, it was assumed that the modification procedure
did not result in significant losses. A correction was applied to
account for dilution of the sample.
Online High-Performance Size Exclusion
Chromatography Light Scattering
Online high performance-size exclusion chromatography
light scattering was performed using a 7.8 · 300 mm TSKgel
G2000SWXL column (Tosoh Bioscience, Stuttgart, Germany) in
a single column mode on a HP1100 analytical chromatography
system (Hewlett-Packard, San Jose, CA) equipped with a built-
in UV detector and a sequential refractive index, intrinsic vis-
cosity, and right angle light scattering detection (TDA 302,
Viscotek, Corp, Houston, TX), as previously described.30
Rabbit Antisera
Two female New Zealand white rabbits were immunized
and boosted 5 times at 4-week intervals with 100 mg/mL of
glutaraldehyde-modified rFel d 1(rFel d 1-mod) from P. pas-
toris. For each immunization, 1 mL of rFel d 1-mod was mixed
with 1 mL of Montanide ISA-50 (Seppic, Paris, France).
Radioallergosorbent Test
For the measurement of specific IgE or IgG against nFel
d 1, rFel d 1, and rFel d 1-mod, a radioallergosorbent test
(RAST) was performed as described previously.31 For IgE, the
results were expressed as international units (IU)/milliliter, and
for IgG, the results were expressed in percent bound activity.
ImmunoCAP Inhibition
ImmunoCAP (Phadia, Uppsala, Sweden) assay was
performed according to the manufacturer’s instructions. For
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CAP-inhibition, a serum pool of cat-allergic patients (n. 100)
was preincubated at room temperature for 1 hour with serial
dilutions of inhibitor, before addition to cat ImmunoCAP (e1).
The following inhibitors were used: nFel d 1, rFel d 1, and rFel
d 1-mod. Results were expressed as percentage inhibition.
Competitive Radioimmunoassay
To quantify Fel d 1 in different samples, a competitive
radioimmunoassay (RIA) or sandwich enzyme-linked immu-
nosorbent assay (ELISA) were used. The competitive RIA
was performed essentially as described elsewhere.32 The Fel
d 1 concentration was calculated using the standard curve of
a house dust extract with known Fel d 1 content (14 U/mL).
One unit was considered to be equivalent to 1 mg Fel d 1.
The sandwich ELISA was developed by Chapman
et al33 (Indoor Biotechnologies, Warminster, United King-
dom). Serial sample dilutions were assayed. Reference Fel
d 1 standard (9.7 U/mL) was used at serial dilutions from
20 to 0.04 mU/mL. Plates were read in an ELISA microplate
reader at 405 nm.
Stripped Basophil Histamine
Release Bioassay
To assess biological activity of Fel d 1, the stripped
basophil histamine release (BHR) bioassay was performed.
White blood cells were isolated from whole blood of a non-
allergic donor by Percoll centrifugation and stripped from IgE
by lactic acid treatment as described elsewhere.34,35 Subse-
quently, cells were resensitized with the patients serum (n ¼
4). Histamine release was performed with nFel d 1, rFel d 1,
and rFel d 1-mod (of 0.01 pg/mL to 100 mg/mL). Liberated
histamine was measured by the fluorometric analysis de-
scribed by Siraganian.36
Allergen-Specific Proliferation of
Freshly Isolated Peripheral Blood
Mononuclear Cells
T-cell reactivity was assessed by measuring prolifera-
tion of peripheral blood mononuclear cells (PBMCs) from
cat-allergic donors to nFel d 1, rFel d 1, and rFel d 1-mod.
PBMCs were plated out at 2 · 105 cells per well in
IMDM (Bio-Whittaker, Walkersville, MD) supplemented
with 5% normal human serum (Bio-Whittaker) and gentami-
cin (80 mg/mL; Duchefa, Haarlem, the Netherlands). Dilution
series of allergen or allergoid (0.03–10 mg/mL) were added at
day 0, followed by addition of 3H-labelled thymidine at day 6,
and harvesting the radioactively labeled cells at day 7 to
measure the Ag-induced proliferation.
RESULTS
Production, Purification, and Modification
of rFel d 1
Constructs encompassing both chains of Fel d 1, either
directly linked together (E. coli) or using a linker sequence
(P. pastoris), were successfully developed. Expression level
in E. coli after 5-hour induction at 308C was 43 mg/mL, as
determined by competitive RIA. In P. pastoris, 400 mg/mL
was reached. rFel d 1 was purified by hydrophobic interaction
chromatography and ion exchange chromatography, giving
a final yield of 92% from E. coli, and the purification efficacy
was similar from yeast. SDS-PAGE (Fig. 1) of nFel d 1 under
reducing conditions revealed 1 discrete band with an apparent
molecular weight (MW) of approximately 4.5 kDa and
a smear between 10 and 16 kDa. For rFel d 1 from P. pas-
toris, 5 bands (5, 7, 10, 17, and 20 kDa) and 2 smears (12–15
kDa and 23–28 kDa) were observed, whereas rFel d 1 from
E. coli gave a single discrete band (MW, w17 kDa). Glutar-
aldehyde modification of E. coli-derived rFel d 1 revealed
2 smears with an apparent MW of 12 to 20 kDa and 29 to
40 kDa, respectively.
N-terminal sequencing of the 17 kDa and 20 kDa bands
from rFel d 1 (P. pastoris) demonstrated that the lower band
is rFel d 1 with the correct N-terminal sequence (EIC-
PAVKRDV),10 and the upper band is rFel d 1 with 9 residual
amino acids originating from the signal peptide, upstream of
the Kex 2 site (EEGVSLEKRE). N-terminal sequencing of
the E. coli-derived 17-kDa band showed that the first 10
amino acids were identical to the N-terminal amino acid se-
quence (b-chain) of Fel d 1 (VKMAETCPIF).10
Native and chemically modified rFel d 1 were charac-
terized regarding molecular size using small-angle x-ray
scattering and dynamic light scattering methodologies, both
FIGURE 1. SDS-PAGE analysis of Fel d 1 preparations. SDS-
PAGE was performed under reducing conditions and silver
stained. Lane 1: blue plus marker (Invitrogen); lane 2: nFel d 1;
lane 3: rFel d 1 (P. pastoris); lane 4: rFel d 1; and lane 5:
glutaraldehyde-modified rFel d 1.
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resulting in highly polydisperse mixtures of molecules (data
not shown). These mixtures were separated by online high-
performance size exclusion chromatography, and the values
for MW and hydrodynamic radius (RH) of eluting fractions
were determined by online light scattering and viscosimetry
(Fig. 2). The main fraction of native Fel d 1 (representing
w56% of the protein) was determined to be approximately
18 kDa, corresponding to monomeric Fel d 1. Small
oligomers (MW, 48 kDa; RH 3.3 nm) represented 22% and
larger oligomers (MW.85 kD; RH. 5 nm) 16% represented
of protein. In addition, approximately 6% of highly aggre-
gated protein, accounting for strong light scattering intensity,
were detected. Chemical modification of rFel d 1 caused for-
mation of polymers with a MW of $1 mDa. Three different
major fractions were found spanning large regions of the
chromatogram.
Comparison of Immune-Reactivity of
Natural and Recombinant Fel d 1
The IgE-binding characteristics of rFel d 1 were
assessed by RAST, immunoblot, and CAP inhibition. Sera
of cat-sensitized patients (n ¼ 76) were tested in a RAST for
specific IgE antibodies against nFel d 1 and rFel d 1 (Fig. 3).
By Spearman rank correlation, IgE responses to nFel d 1 and
rFel d 1 were shown to closely correlate (Rs ¼ 0.9150) [95%
confidence interval, 0.8680–0.9458; P , 0.0001]. Overall,
binding to rFel d 1 was slightly higher than to nFel d 1 (mean
ratio, 1.3; 95% confidence interval, 0.85–1.75). Five patients
were monosensitized to nFel d 1 (,2 IU/mL), but with low
specific IgE titers, and 1 was .5 times more reactive to nFel
d 1 than to the recombinant. On immunoblot, IgE reactivity to
rFel d 1 was detected at 16 kDa, in some cases accompanied
by a faint band at approximately 38 kDa, presumably repre-
senting the rFel d 1 dimer (Fig. 4). mAb 4F7 raised to purified
nFel d 1 and both chain-specific mAbs bound to the same 16
kDa band. mAb 6B4 (specific for the light a-chain) also
detected the 38-kDa band, confirming the Fel d 1 nature of
this band. Comparing IgE-binding potencies of natural Fel d 1
and rFel d 1 with ImmunoCAP inhibition, using a serum pool
of cat-sensitized subjects, demonstrated that both preparations
have very similar inhibitory potencies (Fig. 5A). Addition-
ally, the biological activity of both molecules assessed by
BHR was comparable (Fig. 5B). Competitive RIA with poly-
clonal rabbit antiserum against nFel d 1 and 125I-labelled nFel
d 1 (Fig. 5C) further confirmed the similarity. Only the sand-
wich ELISA based on 2 mAbs showed preference for nFel d 1
by a factor 6 (Fig. 5D). Overall, rFel d 1 is a good mimic of its
natural counterpart. Comparable results were obtained with
yeast-derived rFel d 1 (not shown).
Modified rFel d 1: Reduced IgE and IgG
Antibody Binding
Glutaraldehyde-modified rFel d 1 was evaluated by
CAP inhibition, competitive RIA, and ELISA. The IgE-
binding potency in CAP inhibition was reduced by .3 orders
of magnitude (w1300-fold) compared with the unmodified
recombinant allergen (Fig. 5A). Although the magnitude of
reduction observed in competitive RIA (Fig. 5C) and ELISA
(Fig. 5D) was not identical (w500-fold and w5000-fold, re-
spectively), it was highly significant in both cases. Similar
results were obtained with yeast-derived rFel d 1 (not shown).
Modified rFel d 1: Reduced
Biological Activity
The biological activity of rFel d 1-mod was assessed by
the stripped BHR bioassay (n ¼ 4). In the first experiment,
FIGURE 2. Determination of molecular size under
physiological conditions. Refractive index signal and MW for
native (black) and modified (gray) rFel d 1 determined by
online high-performance size exclusion chromatography light
scattering. Determined MW values of the eluting fractions
(native: vret ¼ 5.6–7.3 mL, 7.6–7.8 mL, and 8.6–8.9 mL;
modified: vret ¼ 5.6–6.8 mL, 7.2–7.4 mL, and 8.0–8.3 mL) are
shown in thin dashed lines.
FIGURE 3. Comparison of IgE binding of natural versus
recombinant Fel d 1. IgE responses to nFel d 1 (x axis) were
compared with rFel d 1 (y axis) by RAST using sera of 76 cat-
allergic patients. Results are expressed in IE/mL. Decreased
reactivity toward rFel d 1 was observed for (5 of 76) sera. The
filled circles are exclusively positive for nFel d 1, and the filled
triangle was 5 times more reactive to nFel d1 than to rFel d 1.
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modified rFel d demonstrated .1000-fold reduced reactivity
compared with unmodified rFel d 1, but an accurate assess-
ment was not possible because the native allergen was not
diluted far enough (not shown). In a follow-up experiment,
for 2 of the 4 original sera, native allergen was diluted up to
0.01 pg/mL, allowing a more accurate calculation. rFel d
1-mod showed a decrease in biological activity of .106-fold
(Fig. 5B). Significant reduction (1000-fold) was observed for
yeast-derived rFel d 1-mod (not shown). The stripped cells
(negative control) showed a release of ,4% (not shown).
Modified rFel d 1: Retained
T-cell Proliferation
PBMCs from 4 cat-allergic patients were stimulated
with dilutions of nFel d 1, rFel d 1, and rFel d 1-mod (Fig. 6).
The mean stimulation index at 10 mg/mL was significantly
higher upon stimulation with modified allergen (8.4) than
with the native molecule (5.6) (P , 0.01, Wilcoxon). These
data demonstrated that rFel d 1-mod had retained its capacity
to trigger cat allergen–specific T cells. Similar observations
were made for the yeast-derived recombinant molecule (not
shown).
FIGURE 4. Immunoblotting of purified rFel d 1. Lanes 1 to 3
were detected with 3 Fel d 1-specific mAbs (4F7, 10F10, and
6B4, respectively); lanes 4 and 5 were detected by sera derived
from 2 cat-allergic patients (serum 6 and 154); and lanes 6 and
7 were detected with rFel d 1-mod–specific rabbit polyclonal
antibody (rabbit 140662 and 140831, respectively).
FIGURE 5. Immunological characterization of modified rFel d 1. A, ImmunoCAP inhibition. ImmunoCAP inhibition was
performed with a cat epithelium and dander CAP (e1) and a serum pool of .100 cat-allergic patients. B, Stripped basophile
histamine release assay. C, Competitive RIA. D, Fel d 1–specific sandwich ELISA. E, IgG RAST. Open circle represents nFel d 1, filled
circle represents rFel d 1, and filed square represents rFel d 1-mod.
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Immunogenicity of Modified rFel d 1
To assess the capability of rFel d 1-mod to induce IgG
antibodies recognizing the natural allergen, 2 rabbits were
immunized with the modified allergen from yeast. The
resulting rabbit antisera were tested in RAST and immunoblot
experiments for IgG reactivity with nFel d 1, rFel d 1, and
rFel d 1-mod. IgG antibodies induced upon immunization
with rFel d 1-mod bound in a similar fashion to nFel d 1, rFel
d 1, and rFel d 1-mod (Fig. 5E). Both antisera clearly detected
the unmodified rFel d 1 on immunoblot (Fig. 4).
DISCUSSION
Over the past years, several strategies have been
evaluated in our laboratory to express rFel d 1, starting with
separate expression of both chains of the molecule in P. pas-
toris (unpublished data), and subsequently, the expression of
both chains coupled by a linker sequence (this study). In our
study, this approach resulted in a rFel d 1 preparation with
good immune reactivity but an undesirable degree of molec-
ular heterogeneity caused by hyperglycosylation of a fraction
of the molecules at the N-linked glycosylation site in the
b-chain of Fel d 1. Additionally, some instability of the linker
sequence resulted in partial cleavage of the 2-chain hetero-
dimer (confirmed by N-terminal sequencing of the resulting
fragments). Both posttranslational modifications did not sig-
nificantly affect the immune reactivity, but the observed het-
erogeneity is less favorable from a production standpoint. A
mutant lacking the N-linked glycosylation site showed de-
creased heterogeneity but was still partially cleaved (not
shown). Therefore, we chose to express rFel d 1 as a hetero-
dimer of both chains without the instable linker in E. coli result-
ing in a stable nonglycosylated homogeneous preparation.
Glutaraldehyde modification of this molecule resulted
in a truly hypoallergenic molecule with a reduction in IgE-
binding potency of approximately 1000-fold. This translated
into a negligible biological activity (106-fold reduction). To
our knowledge, this is unmatched by any hypoallergenic strat-
egy using site-directed mutagenesis.
The size distribution in solution demonstrated that
modification of rFel d 1 resulted in a MW $ 1000 kDa.
However, under the denaturating conditions of SDS-PAGE,
part of the rFel d 1-mod migrated at an apparent MW of 12 to
20 kDa and 29 to 40 kDa, indicating that not all aggregation
observed in solution was caused by covalent interactions.
This suggests that glutaraldehyde modification results in po-
lymerized and aggregated molecules of high MW that may
FIGURE 6. Allergen-specific
proliferation of PBMCs. PBMCs from
4 cat-allergic patients were stimulated
with dilutions of nFel d 1 (B), rFel d 1
(C) and rFel d 1-mod (n). Panels A-D
each represent an individual patient.
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also trap monomers and low MW oligomers, which can be
released under reducing and denaturating conditions.
Although the mechanism of allergen-specific immuno-
therapy is still a matter of debate, it is clear that successful
therapy is accompanied by the induction of regulatory T cells
and IgG4 antibodies.
37 It is generally accepted that a novel
immunotherapy product should have the potency to trigger
allergen-specific T cells. Modified rFel d 1 was shown to
induce at least similar T-cell proliferation as its unmodified
counterpart. Additionally, a role in immunotherapy of IgG4 as
blocking antibodies is likely and we demonstrated that immu-
nization of rabbits with modified rFel d 1–induced specific
IgG antibodies that were able to bind to native Fel d 1.
In summary, it was convincingly demonstrated that
chemical modification of a recombinant allergen is an easy
and highly effective way to achieve hypoallergenicity. This
approach will allow safe administration of higher doses of
allergen to achieve better efficacy.
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